悦康药业：YKYY013注射液获FDA临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical (688658) announced that its subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials for YKYY013 injection for the treatment of chronic hepatitis B virus infection [1] Company Summary - Yuyuan Pharmaceutical's subsidiary has obtained FDA approval for clinical trials [1] - The drug YKYY013 is aimed at treating chronic hepatitis B virus infection [1] Industry Summary - The approval from the FDA highlights the ongoing developments in the pharmaceutical industry, particularly in the area of hepatitis B treatments [1]